The research team at Inflamax Research in Mississauga, Ontario is seeking children (5-11 years of age) and youth (12-17 years of age) with a peanut allergy, and no history of anaphylaxis, to participate in a new investigational immunotherapy study for peanut allergy.
Please see their call for participants below for more details. If your child is interested in participating, we encourage you to contact the research team directly to learn more about potential risks and benefits of this study, and to also speak with your child’s physician.
Please note, the call for participants ends on July 15, 2018.
From the research team
Inflamax Research in Mississauga, is looking to speak to parents with children and adolescents with peanut allergies. Following is their announcement:
Currently, there is no effective treatment for peanut allergy other than avoidance of peanut allergens. Our experienced research team, led by Dr. Peter Couroux, is working closely with pharmaceutical organizations to explore therapies for people with peanut allergies. Currently we are conducting a peanut allergy study for children and adolescents. The details for each age group is summarized below:
FOR CHILDREN (5-11 YEARS)
We are currently conducting a general screening for food allergies. This general screening will help us determine eligible candidates for an upcoming peanut allergy study at Inflamax Research. No medication will be administered or tested during this screening assessment.
Eligibility
- Participants: Must be between 5 to 11 years of age (parent/guardian must sign a consent form)
- Diagnosis: Your child must have received a peanut allergy diagnosis from an allergist, family doctor, or pediatrician. Participants should not have a history of anaphylaxis.
How to participate
Participation will involve the following:
- Step 1: Passing a telephone questionnaire (approximately a 20 minute call with a recruitment coordinator)
- Step 2: Attending a screening visit at the Inflamax Research clinic in Mississauga, Ontario which will take approximately 3 hours. During this visit, a detailed medical and allergy history, physical examination and blood work will be conducted during the screening. The results of this assessment will help us to determine if your child is eligible for an upcoming allergy study.
Participants will be compensated with $50 for the screening visit.
FOR ADOLESCENTS (12-17 YEARS)
We are currently enrolling adolescents in a study examining the safety and tolerability of an investigational modified peanut protein subcutaneous immunotherapy. If you are a parent of an adolescent with a peanut allergy, we invite you to contact us about a current peanut allergy study.
Eligibility
- Participants: Must be between 12 to 17 years of age (parent/guardian must sign a consent form)
- Diagnosis: Your child must have received a peanut allergy diagnosis from an allergist, family doctor, or pediatrician. Participants should not have a history of anaphylaxis.
- Other: Your child must be able to travel to our Mississauga clinic for weekly visits that last 5 hours in duration.
How to participate
Participation will involve the following:
- Step 1: Passing a telephone questionnaire (approximately a 20 minute call with a recruitment coordinator)
- Step 2: Attending a screening visit at the Inflamax Research clinic in Mississauga, Ontario
- Step 3: Once your child is deemed eligible for the study, there will be 15 visits to the Inflamax Research clinic to complete the subcutaneous dosing schedule (each visit will last approximately 5 hours)
- Step 4: Participating in a few follow-up phone calls upon completing the dosing schedule
The study should take around 4 months to complete and each clinic visit will last around 5 hours. Participants who successfully complete the study will receive a maximum compensation up to $4250.
CONFIDENTIALITY
Participation in these studies is entirely voluntary. You may refuse to participate or you may discontinue your participation at any time without explanation. All information obtained during these studies will be kept strictly confidential to the extent allowable by law. The research data will be available only to the research team. This study has been reviewed by IRB Services, an independent Research Ethics Board.
QUESTIONS
If you have any questions, please contact Jodi Graham, at jgraham@inflamaxresearch.com or call 905-282-1808
REGISTRATION
Click on this link to register: www.sneezetoronto.com
Registration will be open until: 15-Jul-2018
Tags: call for participation, immunotherapy study, peanut allergy